Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,431
archived clinical trials in
Anemia

Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Bronx, NY
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Buffalo, NY
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Buffalo, NY
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
New Hyde Park, NY
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
New York, NY
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Valhalla, NY
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Valhalla, NY
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Charlotte, NC
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Akron, OH
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Akron, OH
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Cincinnati, OH
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Cleveland, OH
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Cleveland, OH
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Columbus, OH
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Portland, OR
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Portland, OR
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Philadelphia, PA
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Dallas, TX
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Houston, TX
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Houston, TX
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
San Antonio, TX
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Charlottesville, VA
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Norfolk, VA
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Richmond, VA
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Seattle, WA
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
Clinical Research Facility
mi
from
Washington,
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated:  1/5/2018
mi
from
Edegem,
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
A Multi-Center, Double-Blind, Randomized Study Evaluating De Novo Weekly and Once Every Two Week Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Receiving and Not Receiving Dialysis
Status: Enrolling
Updated: 1/5/2018
mi
from
Edegem,
Click here to add this to my saved trials
Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma
Dysregulation of Hematopoiesis in Fanconi Anemia
Status: Enrolling
Updated:  1/8/2018
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma
Dysregulation of Hematopoiesis in Fanconi Anemia
Status: Enrolling
Updated: 1/8/2018
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
IV Iron for the Anemia of Traumatic Critical Illness
A Multicenter, Randomized, Double-blind Comparison of Intravenous Iron Supplementation to Placebo for the Treatment of Anemia of Traumatic Critical Illness
Status: Enrolling
Updated:  1/10/2018
Johns Hopkins Hospital
mi
from
Baltimore, MD
IV Iron for the Anemia of Traumatic Critical Illness
A Multicenter, Randomized, Double-blind Comparison of Intravenous Iron Supplementation to Placebo for the Treatment of Anemia of Traumatic Critical Illness
Status: Enrolling
Updated: 1/10/2018
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
IV Iron for the Anemia of Traumatic Critical Illness
A Multicenter, Randomized, Double-blind Comparison of Intravenous Iron Supplementation to Placebo for the Treatment of Anemia of Traumatic Critical Illness
Status: Enrolling
Updated:  1/10/2018
NewYork Presbyterian Medical Center/Weill Cornell Medical College
mi
from
New York, NY
IV Iron for the Anemia of Traumatic Critical Illness
A Multicenter, Randomized, Double-blind Comparison of Intravenous Iron Supplementation to Placebo for the Treatment of Anemia of Traumatic Critical Illness
Status: Enrolling
Updated: 1/10/2018
NewYork Presbyterian Medical Center/Weill Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
IV Iron for the Anemia of Traumatic Critical Illness
A Multicenter, Randomized, Double-blind Comparison of Intravenous Iron Supplementation to Placebo for the Treatment of Anemia of Traumatic Critical Illness
Status: Enrolling
Updated:  1/10/2018
Univ of Pennsylvania
mi
from
Philadelphia, PA
IV Iron for the Anemia of Traumatic Critical Illness
A Multicenter, Randomized, Double-blind Comparison of Intravenous Iron Supplementation to Placebo for the Treatment of Anemia of Traumatic Critical Illness
Status: Enrolling
Updated: 1/10/2018
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
IV Iron for the Anemia of Traumatic Critical Illness
A Multicenter, Randomized, Double-blind Comparison of Intravenous Iron Supplementation to Placebo for the Treatment of Anemia of Traumatic Critical Illness
Status: Enrolling
Updated:  1/10/2018
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
IV Iron for the Anemia of Traumatic Critical Illness
A Multicenter, Randomized, Double-blind Comparison of Intravenous Iron Supplementation to Placebo for the Treatment of Anemia of Traumatic Critical Illness
Status: Enrolling
Updated: 1/10/2018
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
IV Iron for the Anemia of Traumatic Critical Illness
A Multicenter, Randomized, Double-blind Comparison of Intravenous Iron Supplementation to Placebo for the Treatment of Anemia of Traumatic Critical Illness
Status: Enrolling
Updated:  1/10/2018
Harborview Medical Center at University of Washington
mi
from
Seattle, WA
IV Iron for the Anemia of Traumatic Critical Illness
A Multicenter, Randomized, Double-blind Comparison of Intravenous Iron Supplementation to Placebo for the Treatment of Anemia of Traumatic Critical Illness
Status: Enrolling
Updated: 1/10/2018
Harborview Medical Center at University of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
IV Iron for the Anemia of Traumatic Critical Illness
A Multicenter, Randomized, Double-blind Comparison of Intravenous Iron Supplementation to Placebo for the Treatment of Anemia of Traumatic Critical Illness
Status: Enrolling
Updated:  1/10/2018
University of Michigan Health Systems
mi
from
Ann Arbor, MI
IV Iron for the Anemia of Traumatic Critical Illness
A Multicenter, Randomized, Double-blind Comparison of Intravenous Iron Supplementation to Placebo for the Treatment of Anemia of Traumatic Critical Illness
Status: Enrolling
Updated: 1/10/2018
University of Michigan Health Systems
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Phase II Trial of Regadenoson in Sickle Cell Anemia
A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia
Status: Enrolling
Updated:  1/10/2018
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
A Phase II Trial of Regadenoson in Sickle Cell Anemia
A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia
Status: Enrolling
Updated: 1/10/2018
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
A Phase II Trial of Regadenoson in Sickle Cell Anemia
A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia
Status: Enrolling
Updated:  1/10/2018
University of Illinois at Chicago
mi
from
Chicago, IL
A Phase II Trial of Regadenoson in Sickle Cell Anemia
A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia
Status: Enrolling
Updated: 1/10/2018
University of Illinois at Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase II Trial of Regadenoson in Sickle Cell Anemia
A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia
Status: Enrolling
Updated:  1/10/2018
Johns Hopkins University
mi
from
Baltimore, MD
A Phase II Trial of Regadenoson in Sickle Cell Anemia
A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia
Status: Enrolling
Updated: 1/10/2018
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Phase II Trial of Regadenoson in Sickle Cell Anemia
A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia
Status: Enrolling
Updated:  1/10/2018
Boston Children's Hospital
mi
from
Boston, MA
A Phase II Trial of Regadenoson in Sickle Cell Anemia
A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia
Status: Enrolling
Updated: 1/10/2018
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase II Trial of Regadenoson in Sickle Cell Anemia
A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia
Status: Enrolling
Updated:  1/10/2018
Brigham and Women's Hosp
mi
from
Boston, MA
A Phase II Trial of Regadenoson in Sickle Cell Anemia
A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia
Status: Enrolling
Updated: 1/10/2018
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase II Trial of Regadenoson in Sickle Cell Anemia
A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia
Status: Enrolling
Updated:  1/10/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Phase II Trial of Regadenoson in Sickle Cell Anemia
A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia
Status: Enrolling
Updated: 1/10/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase II Trial of Regadenoson in Sickle Cell Anemia
A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia
Status: Enrolling
Updated:  1/10/2018
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
A Phase II Trial of Regadenoson in Sickle Cell Anemia
A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia
Status: Enrolling
Updated: 1/10/2018
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Phase II Trial of Regadenoson in Sickle Cell Anemia
A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia
Status: Enrolling
Updated:  1/10/2018
Duke University
mi
from
Durham, NC
A Phase II Trial of Regadenoson in Sickle Cell Anemia
A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia
Status: Enrolling
Updated: 1/10/2018
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
A Phase II Trial of Regadenoson in Sickle Cell Anemia
A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia
Status: Enrolling
Updated:  1/10/2018
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
A Phase II Trial of Regadenoson in Sickle Cell Anemia
A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia
Status: Enrolling
Updated: 1/10/2018
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Phase II Trial of Regadenoson in Sickle Cell Anemia
A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia
Status: Enrolling
Updated:  1/10/2018
Baylor College of Medicine
mi
from
Houston, TX
A Phase II Trial of Regadenoson in Sickle Cell Anemia
A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia
Status: Enrolling
Updated: 1/10/2018
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase II Trial of Regadenoson in Sickle Cell Anemia
A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia
Status: Enrolling
Updated:  1/10/2018
Medical College of Wisconsin
mi
from
Milwaukee, WI
A Phase II Trial of Regadenoson in Sickle Cell Anemia
A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia
Status: Enrolling
Updated: 1/10/2018
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Phase II Trial of Regadenoson in Sickle Cell Anemia
A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia
Status: Enrolling
Updated:  1/10/2018
Washington University in St. Louis
mi
from
Saint Louis, MO
A Phase II Trial of Regadenoson in Sickle Cell Anemia
A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia
Status: Enrolling
Updated: 1/10/2018
Washington University in St. Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Randomized Study Comparing Ferric Carboxymaltose to Iron Sucrose to Treat Fe Deficiency in the Surgically Critically Ill
A Randomized Pilot Study of Ferric Carboxymaltose as Compared to Iron Sucrose for the Treatment of Functional Iron Deficiency Associated With Surgical Critical Illness
Status: Enrolling
Updated:  1/10/2018
Denver Health Medical Center
mi
from
Denver, CO
Randomized Study Comparing Ferric Carboxymaltose to Iron Sucrose to Treat Fe Deficiency in the Surgically Critically Ill
A Randomized Pilot Study of Ferric Carboxymaltose as Compared to Iron Sucrose for the Treatment of Functional Iron Deficiency Associated With Surgical Critical Illness
Status: Enrolling
Updated: 1/10/2018
Denver Health Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Functional Neuroimaging of Pain Using EEG and fMRI
Functional Neuroimaging of Pain in Sickle Cell Disease Patients
Status: Enrolling
Updated:  1/11/2018
Biomedical Engineering Department
mi
from
Minneapolis, MN
Functional Neuroimaging of Pain Using EEG and fMRI
Functional Neuroimaging of Pain in Sickle Cell Disease Patients
Status: Enrolling
Updated: 1/11/2018
Biomedical Engineering Department
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Vitamin D3 in Patients With Sickle Cell Disease
Nutritional Vitamin D3 in Patients With Sickle Cell Disease
Status: Enrolling
Updated:  1/17/2018
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Vitamin D3 in Patients With Sickle Cell Disease
Nutritional Vitamin D3 in Patients With Sickle Cell Disease
Status: Enrolling
Updated: 1/17/2018
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Safety Assessment of Iron Sucrose (Venofer) in Patients With Chronic Kidney Disease Who Cannot Tolerate Ferumoxytol (Feraheme) or Iron Dextran (INFed or Dexferrum)
Assessment of Safety of Iron Sucrose (Venofer) in Patients With Chronic Kidney Disease Who Cannot Tolerate Ferumoxytol (Feraheme) or Iron Dextran (INFed or Dexferrum)
Status: Enrolling
Updated:  1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Safety Assessment of Iron Sucrose (Venofer) in Patients With Chronic Kidney Disease Who Cannot Tolerate Ferumoxytol (Feraheme) or Iron Dextran (INFed or Dexferrum)
Assessment of Safety of Iron Sucrose (Venofer) in Patients With Chronic Kidney Disease Who Cannot Tolerate Ferumoxytol (Feraheme) or Iron Dextran (INFed or Dexferrum)
Status: Enrolling
Updated: 1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Click here to add this to my saved trials
Observational Study on the Use of IV (Intravenous) Iron Therapy Among Subjects With Iron Deficiency Anemia
Observational Study on the Use of IV (Intravenous) Iron Therapy Among Subjects With Iron Deficiency Anemia
Status: Enrolling
Updated:  1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Observational Study on the Use of IV (Intravenous) Iron Therapy Among Subjects With Iron Deficiency Anemia
Observational Study on the Use of IV (Intravenous) Iron Therapy Among Subjects With Iron Deficiency Anemia
Status: Enrolling
Updated: 1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Click here to add this to my saved trials
Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia
A Blinded, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer (Ferric Carboxymaltose) in the Treatment of Iron Deficient Patients With Fibromyalgia
Status: Enrolling
Updated:  1/22/2018
Clinical Research Solutions
mi
from
Franklin, TN
Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia
A Blinded, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer (Ferric Carboxymaltose) in the Treatment of Iron Deficient Patients With Fibromyalgia
Status: Enrolling
Updated: 1/22/2018
Clinical Research Solutions
mi
from
Franklin, TN
Click here to add this to my saved trials
Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients
A Multi-center, Randomized Controlled Study to Investigate the Safety and Tolerability of IV Ferric Carboxymaltose (FCM) vs Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients
Status: Enrolling
Updated:  1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients
A Multi-center, Randomized Controlled Study to Investigate the Safety and Tolerability of IV Ferric Carboxymaltose (FCM) vs Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients
Status: Enrolling
Updated: 1/22/2018
Luitpold Pharmaceuticals, Inc.
mi
from
Norristown, PA
Click here to add this to my saved trials